A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Phase Ia Study in Healthy Adult Subjects to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of SYHA1805
Overview
- Phase
- Phase 1
- Intervention
- Placebo
- Conditions
- Healthy Subjects
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Enrollment
- 40
- Primary Endpoint
- Number of Participants with One or More Serious Adverse Event(s) (SAEs) or non-serious adverse events (AEs) Considered by the Investigator to be Related to Study Drug Administrationorally
- Last Updated
- 5 years ago
Overview
Brief Summary
This is a three-part Phase Ia study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of SYHA1805.
Detailed Description
This trial is divided into three parts: 1) The first part: Four Chinese healthy subjects will be included in the pre-test group to evaluate the safety, tolerability and pharmacokinetics after taking SYHA1805 tablets; 2) The second part: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic characteristics, several single ascending doses of SYHA1805 tablets or matching placebo tablets will be randomly administered to 24 Chinese healthy subjects under fasting condition; 3) The third part :To evaluate the food effect on the pharmacokinetic characteristics, a single dose SYHA1805 tablets will be administered to 12 Chinese healthy subjects under fed or fasted condition.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age: 18 to 45 years of age inclusive;
- •Weight: Body weight ≥50 kg, body mass index (BMI) within the range of 19-28 kg/m2 (inclusive);
- •Overtly healthy as determined by medical evaluation including comprehensive physical examinations, vital signs, laboratory examinations, ECG examination, color Doppler ultrasound (abdominal color Doppler ultrasound, heart color Doppler ultrasound), chest X-ray, etc.;
- •Agree to use highly effective contraceptive methods (such as condoms or intrauterine devices, contraceptive drugs) during the clinical trial period (screening period to 30 days after the last dose). Male subject refrains from sperm donation;
- •Fully understand the content and possible adverse reactions of the test drug, have the ability to communicate with investigators normally, and able to comply with the research requirements(such as: visit on time, and follow the procedures, restrictions and requirements of the protocol);
- •Volunteer to participate in the study and sign the informed consent form.
Exclusion Criteria
- •Have history or other underlying risk factors of torsade de pointes ventricular tachycardia, short QT syndrome, long QT syndrome. Have first-degree relatives (biological parents, siblings or children) who suffered from sudden death in young age (less than/equal to 40 years old), drowning or sudden infant death syndrome of unknown cause ;
- •Have history of malignant tumors, mental illness, depression, anxiety, and epilepsy;
- •Have history of drugs abuse in the past 3 years. or positive drug test at screening;
- •Have history of clinically significant drug allergies, or a history of atopic allergic diseases (asthma, urticaria, eczema dermatitis), or those who are known to be allergic to experimental drug excipients or the same type of drugs;
- •The investigator determines that the subjects have disease that affect drug absorption, distribution, metabolism, or excretion, such as:
- •History of inflammatory bowel disease, gastritis, ulcers, bile duct stones, gastrointestinal or or rectal bleeding;
- •History of major gastrointestinal surgery (gastrectomy, gastrointestinal anastomosis, or bowel resection);
- •History or clinical evidence of pancreatic injury or pancreatitis;
- •ALT, AST, and total serum bilirubin are greater than 2 times the upper limits of normal (ULN) or other liver function test abnormalities, and the abnormalities are determined by the investigator to have clinical significance, suggesting liver disease or liver damage;
- •Renal function suggests that the creatinine clearance rate is less than 90 mL/min, or has urinary tract obstruction or difficulty in emptying urine;
Arms & Interventions
Placebo
Subjects will receive the matching placebo tablets.
Intervention: Placebo
Outcomes
Primary Outcomes
Number of Participants with One or More Serious Adverse Event(s) (SAEs) or non-serious adverse events (AEs) Considered by the Investigator to be Related to Study Drug Administrationorally
Time Frame: Baseline through Day 28
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Secondary Outcomes
- Area under the plasma concentration versus time curve (AUC)(Baseline through Day 28)
- Peak Plasma Concentration (Cmax)(Baseline through Day 28)
- Apparent clearance (CL/F)(Baseline through Day 28)
- To evaluate the ECG result of single doses of SYHA1805 administered orally(Baseline through Day 28)
- Time to maximum plasma concentration（Tmax）(Baseline through Day 28)
- Half time (t1/2)(Baseline through Day 28)